<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39391264</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1432-2277</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Transplant international : official journal of the European Society for Organ Transplantation</Title><ISOAbbreviation>Transpl Int</ISOAbbreviation></Journal><ArticleTitle>Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience.</ArticleTitle><Pagination><StartPage>12920</StartPage><MedlinePgn>12920</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12920</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/ti.2024.12920</ELocationID><Abstract><AbstractText>Patients undergoing kidney transplant are at risk of severe COVID-19. Our single-center retrospective analysis evaluated the outcomes of kidney transplant outpatients with COVID-19 who were managed with reduced immunosuppression and treatment with molnupiravir. Between January 2022 and May 2023, we included 93 patients (62 men, average age 56 years), serum creatinine 127 (101-153) µmol/L. Molnupiravir was administered, and immunosuppressive therapy was reduced immediately following the confirmation of SARS-CoV-2 infection by PCR, which was 2 (1-3) days after the onset of symptoms. Only three (3.2%) patients required hospitalization, and one patient died. Acute kidney injury was observed in two patients. During the follow-up period of 19 (15-22) months, there was no significant increase in proteinuria, no acute or new chronic graft rejection, and kidney graft function remained stable; serum creatinine was 124 (106-159) µmol/L post-COVID-19 infection and 128 (101-161) µmol/L at the end of the follow-up period. Our results demonstrate that early initiation of molnupiravir treatment combined with a temporary reduction in immunosuppressive therapy results in favorable clinical outcomes in patients with COVID-19, with preservation of good graft function and no episodes of graft rejection.</AbstractText><CopyrightInformation>Copyright © 2024 Matysková Kubišová, Dusilová Sulková, Moučka, Pokorná, Heislerová, Guňka, Navrátil, Pacovský, Malá and Šafránek.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matysková Kubišová</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dusilová Sulková</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moučka</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pokorná</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heislerová</LastName><ForeName>Marcela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Pharmacy, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guňka</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navrátil</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacovský</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malá</LastName><ForeName>Alena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Šafránek</LastName><ForeName>Roman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nephrology, University Hospital Hradec Kralove, Hradec Králové, Czechia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Transpl Int</MedlineTA><NlmUniqueID>8908516</NlmUniqueID><ISSNLinking>0934-0874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="Y">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Sars-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral drugs</Keyword><Keyword MajorTopicYN="N">kidney transplantation</Keyword><Keyword MajorTopicYN="N">molnupiravir</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39391264</ArticleId><ArticleId IdType="pmc">PMC11464333</ArticleId><ArticleId IdType="doi">10.3389/ti.2024.12920</ArticleId><ArticleId IdType="pii">12920</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al. Results From the ERA-EDTA Registry Indicate a High Mortality Due to COVID-19 in Dialysis Patients and Kidney Transplant Recipients across Europe. Kidney Int (2020) 98:1540–8. 10.1016/j.kint.2020.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.09.006</ArticleId><ArticleId IdType="pmc">PMC7560263</ArticleId><ArticleId IdType="pubmed">32979369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran W, Shah P, Barker L, Langlee J, Freed K, Boyer L, et al. COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge. Transplantation (2022) 106(7):e346–e347. 10.1097/TP.0000000000004162</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004162</ArticleId><ArticleId IdType="pmc">PMC9213060</ArticleId><ArticleId IdType="pubmed">35404880</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandolfini I, Crespo M, Hellemans R, Maggiore U, Mariat C, Mjoen G, et al. Issues Regarding COVID-19 in Kidney Transplantation in the ERA of the Omicron Variant: A Commentary by the ERA Descartes Working Group. Nephrol Dial Transpl (2022) 37(10):1824–9. 10.1093/ndt/gfac203</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfac203</ArticleId><ArticleId IdType="pmc">PMC9278231</ArticleId><ArticleId IdType="pubmed">35746885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk BA, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos RV, et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N Engl J Med (2022) 386(6):509–20. 10.1056/NEJMoa2116044</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter, Suppl (2012)(2) 1–138. 10.1038/kisup.2012.6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/kisup.2012.6</ArticleId></ArticleIdList></Reference><Reference><Citation>Poznanski P, Augustyniak-Bartosik H, Magiera-Zak A, Skalec KJ, Jakuszko K, Mazanowska O, et al. Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients. Viruses (2022) 14:2224. 10.3390/v14102224</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102224</ArticleId><ArticleId IdType="pmc">PMC9610487</ArticleId><ArticleId IdType="pubmed">36298779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho WJ, Harden D, Moreno D, Dinulos JE, Hanna PE, Wang Q, et al. Oral Antiviral Therapies for COVID-19 in Patients With Advanced Chronic Kidney Disease or Kidney Failure. Nephrol Dial Transpl (2023) 38:1912–4. 10.1093/ndt/gfad058</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfad058</ArticleId><ArticleId IdType="pmc">PMC10387392</ArticleId><ArticleId IdType="pubmed">36948600</ArticleId></ArticleIdList></Reference><Reference><Citation>Villamarín M, Márquez-Algaba E, Esperalba J, Perelló M, Los Arcos I, Campany D, et al. Preliminary Clinical Experience of Molnupiravir to Prevent Progression of COVID-19 in Kidney Transplant Recipients. Transplantation (2022) 106(11):2200–4. 10.1097/TP.0000000000004306</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004306</ArticleId><ArticleId IdType="pubmed">35915545</ArticleId></ArticleIdList></Reference><Reference><Citation>Radcliffe C, Palacios CF, Azar MM, Cohen E, Malinis M. Real-World Experience With Available, Outpatient COVID-19 Therapies in Solid Organ Transplant Recipients During the Omicron Surge. Am J Transpl (2022) 22(10):2458–63. 10.1111/ajt.17098</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.17098</ArticleId><ArticleId IdType="pmc">PMC9348251</ArticleId><ArticleId IdType="pubmed">35583664</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson MG, Strizki JM, Brown ML, Wan H, Shamsuddin HH, Ramgopal M, et al. Molnupiravir for the Treatment of COVID-19 in Immunocompromised Participants: Efficacy, Safety, and Virology Results From the Phase 3 Randomized, Placebo-Controlled MOVe-OUT Trial. Infection (2023) 51:1273–84. 10.1007/s15010-022-01959-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01959-9</ArticleId><ArticleId IdType="pmc">PMC9844162</ArticleId><ArticleId IdType="pubmed">36648627</ArticleId></ArticleIdList></Reference><Reference><Citation>Guermazi D, Avanitis P, Farmakiotis D. Molnupiravir Efficacy Among Immunocompromised Patients With COVID-19: No Proof of Concept. Infection (2023) 51:1593–5. 10.1007/s15010-023-02027-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02027-6</ArticleId><ArticleId IdType="pmc">PMC10066965</ArticleId><ArticleId IdType="pubmed">37004695</ArticleId></ArticleIdList></Reference><Reference><Citation>Czarnecka K, Czarnecka P, Tronina O, Durlik M. Molnupiravir Outpatient Treatment for Adults With COVID-19 in a Real-World Setting – A Single Center Experience. J Clin Med (2022) 11:6464. 10.3390/jcm11216464</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11216464</ArticleId><ArticleId IdType="pmc">PMC9656557</ArticleId><ArticleId IdType="pubmed">36362691</ArticleId></ArticleIdList></Reference><Reference><Citation>Standing JF, Buggiotti L, Guerra-Assuncao JA, Woodall M, Ellis S, Agyeman AA, et al. Randomized Controlled Trial of Molnupiravir SARS-CoV-2 Viral and Antibody Response in At-Risk Adult Outpatients. Nat Commun (2024) 15(1):1652. 10.1038/s41467-024-45641-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-45641-0</ArticleId><ArticleId IdType="pmc">PMC10891158</ArticleId><ArticleId IdType="pubmed">38396069</ArticleId></ArticleIdList></Reference><Reference><Citation>Fountain-Jones NM, Vanhaeften R, Williamson J, Maskell J, I-Ly JC, Charleston M, et al. Effect of Molnupiravir on SARS-CoV-2 Evolution in Immunocompromised Patients: A Retrospective Observational Study. Lancet Microbe (2024) 5:e452–58. 10.1016/S2666-5247(23)00393-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00393-2</ArticleId><ArticleId IdType="pubmed">38527471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Noorden R, et al. How COVID Vaccines Shaped 2021 in Eight Powerful Charts. Nature (2021) 600:580–3. 10.1038/d41586-021-03686-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03686-x</ArticleId><ArticleId IdType="pubmed">34916666</ArticleId></ArticleIdList></Reference><Reference><Citation>Watschinger C, Stampfel G, Zollner A, Hoog AM, Rössler A, Reiter S, et al. B and T Cell Responses to SARS-CoV-2 Vaccination in Kidney and Liver Transplant Recipients With and Without Previous COVID-19. Viruses (2023) 16(1):1. 10.3390/v16010001</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16010001</ArticleId><ArticleId IdType="pmc">PMC10820906</ArticleId><ArticleId IdType="pubmed">38275936</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh K, Kang M, Kim YE, Choi Y, An SJ, Seong J, et al. Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients. J Infect Dis (2023) 229:1026–34. 10.1093/infdis/jiad501</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad501</ArticleId><ArticleId IdType="pubmed">38097377</ArticleId></ArticleIdList></Reference><Reference><Citation>Manothummetha K, Chuleerarux N, Sanguankeo A, Kates OS, Hirankarn N, Thongkam A, et al. Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis. JAMA Netw Open (2022) 5(4):e226822. 10.1001/jamanetworkopen.2022.6822</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.6822</ArticleId><ArticleId IdType="pmc">PMC9006106</ArticleId><ArticleId IdType="pubmed">35412626</ArticleId></ArticleIdList></Reference><Reference><Citation>Solera JT, Árbol BG, Mittal A, Hall VG, Marinelli T, Bahinskaya I, et al. COVID-19 Reinfection Has Better Outcomes Than the First Infection in Solid Organ Transplant Recipients. Transplantation (2024) 108:1249–56. 10.1097/TP.0000000000004902</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004902</ArticleId><ArticleId IdType="pubmed">38291585</ArticleId></ArticleIdList></Reference><Reference><Citation>Vankova B, Mala-Ladova K, Kubena AA, Maly J, Sulkova SD. Immunosuppressive Therapy Related Adherence, Beliefs and Self-Management in Kidney Transplant Outpatients. Patient Prefer Adherence (2018) 12:2605–13. 10.2147/PPA.S184166</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S184166</ArticleId><ArticleId IdType="pmc">PMC6287542</ArticleId><ArticleId IdType="pubmed">30584284</ArticleId></ArticleIdList></Reference><Reference><Citation>Elec AD, Oltean M, Goldis P, Cismaru C, Lupse M, Muntean A, et al. COVID-19 After Kidney Transplantation: Early Outcomes and Renal Function Following Antiviral Treatment. Int J Infect Dis (2021) 104:426–32. 10.1016/j.ijid.2021.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.01.023</ArticleId><ArticleId IdType="pmc">PMC7836972</ArticleId><ArticleId IdType="pubmed">33453396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TY, Farghaly S, Cham S, Ttem LL, Sin JH, Rauda R, et al. COVID-19 Pneumonia in Kidney Transplant Recipients: Focus on Immunosuppression Management. Transpl Infect Dis (2020) 22(5):e13378. 10.1111/tid.13378</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.13378</ArticleId><ArticleId IdType="pmc">PMC7361217</ArticleId><ArticleId IdType="pubmed">32573882</ArticleId></ArticleIdList></Reference><Reference><Citation>Demir E, Ucar ZA, Dheir H, Danis R, Yelken B, Uyar M, et al. COVID-19 in Kidney Transplant Recipients: A Multicenter Experience From the First Two Waves of Pandemic. BMC Nephrol (2022) 23(1):183. 10.1186/s12882-022-02784-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-022-02784-w</ArticleId><ArticleId IdType="pmc">PMC9097147</ArticleId><ArticleId IdType="pubmed">35550025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajpai D, Deb S, Bose S, Gandhi C, Modi T, Katyal A, et al. Recovery of Kidney Function After AKI Because of COVID-19 in Kidney Transplant Recipients. Transpl Int (2021) 34(6):1074–82. 10.1111/tri.13886</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.13886</ArticleId><ArticleId IdType="pmc">PMC8250238</ArticleId><ArticleId IdType="pubmed">33884672</ArticleId></ArticleIdList></Reference><Reference><Citation>Defelice G, Giusti S, Jeon H, Killackey M, Paramesh A, Vijay A. Short and Long-Term Outcomes of Kidney Transplant Recipients Diagnosed With COVID-19 Infection: A Single-Center Observational Study. Cureus (2022) 14(11):e31375. 10.7759/cureus.31375</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.31375</ArticleId><ArticleId IdType="pmc">PMC9744398</ArticleId><ArticleId IdType="pubmed">36523681</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>